Skip to main content

Advertisement

Log in

Health care costs of osteopenia, osteoporosis, and fragility fractures in Mexico

  • Original Article
  • Published:
Archives of Osteoporosis Aims and scope Submit manuscript

Abstract

Summary

Different sources were used to estimate the 2010 health care costs of managing low bone density (osteopenia/osteoporosis) plus caring fragility fractures in Mexico at 411 million USD. Figures are projected to rise 42 % by 2020. Preventive and timely interventions are required to decrease the financial burden of these entities.

Introduction

Osteopenia, osteoporosis, and fragility fractures (FF) are a public health concern. The study purpose was to estimate the health care costs of these conditions in Mexico during 2010 and project them to 2015 and 2020.

Methods

Prevalence of osteopenia and osteoporosis was derived from international data. The Mexican version of FRAX® algorithm was used to assess risk for a major FF (hip, clinical spine, forearm, and proximal humerus) in osteopenic and osteoporotic population aged over 40 years. The estimates were applied to national demographic projections. Only direct medical costs composed by routine non-pharmacological management of osteopenia/osteoporosis besides the costs owing to medical care of major FF were considered into the analysis. Resource use for managing osteopenia/osteoporosis was defined from local sources (clinical practice guidelines, published literature, and expert opinion); unit costs were gathered from official lists. Costs for medical care of FF were based on diagnosis-related groups.

Results

In population aged ≥40 years, prevalence of osteopenia and osteoporosis in 2010 was 32.8 and 8 %, respectively. A total of 75,763 FF occurred that year. Costs of managing osteopenia and osteoporosis were 154.9 million USD, whereas medical costs due to FF reached 256.2 million USD. Therefore, the annual health care costs of these entities in 2010 were 411 million USD. Total costs will be 19.2 % higher in 2015, and by 2020, the figures will have increased by 41.7 %.

Conclusions

Low bone density entails substantial epidemiological and financial burden in Mexico, and their impact will grow considerably during the next years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Anonymous (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129

    Google Scholar 

  2. Keen RW (2003) Burden of osteoporosis and fractures. Curr Osteoporos Rep 1(2):66–70

    Article  PubMed  Google Scholar 

  3. Looker AC, Melton LJ 3rd, Harris TB, Borrud LG, Shepherd JA (2010) Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res 25(1):64–71

    Article  PubMed  Google Scholar 

  4. Lewiecki EM (2008) Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin North Am 35:301–315

    Article  PubMed  Google Scholar 

  5. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301(5):513–521

    Article  CAS  PubMed  Google Scholar 

  6. Vestergaard P, Rejnmark L, Mosekilde L (2009) Loss of life years after a hip fracture. Acta Orthop 80:525–530

    Article  PubMed  Google Scholar 

  7. Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int 20:853–868

    Article  CAS  PubMed  Google Scholar 

  8. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733

    Article  CAS  PubMed  Google Scholar 

  9. Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3–S7

    Article  PubMed  Google Scholar 

  10. Foundation NO (2008) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC

    Google Scholar 

  11. Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186–191

    Article  PubMed  Google Scholar 

  12. Tarricone R (2006) Cost-of-illness analysis. What room in health economics? Health Policy 77:51–63

    Article  PubMed  Google Scholar 

  13. Clark P, Carlos F, Vazquez-Martinez JL (2010) Epidemiology, costs and burden of osteoporosis in Mexico. Arch Osteoporos 5:9–17

    Article  Google Scholar 

  14. Cruz GI, Cisneros DF, Salazar PR, Tejeida LA (2002) Costos institucionales y dificultades en la atención de los pacientes con fracturas por osteoporosis. Acta Ortop Mex 16:292–295

    Google Scholar 

  15. Velasco-Murillo V, Navarrete-Hernández E, Pozos-Cavanzo JL, Ojeda-Mijares RI, Camacho-Rodríguez MA (2003) Fracturas en mujeres postmenopáusicas en el IMSS: frecuencia y costos de su atención hospitalaria. Gac Med Mex 139:453–458

    PubMed  Google Scholar 

  16. Clark P, Carlos F, Barrera C, Guzman J, Maetzel A, Lavielle P, Ramirez E, Robinson V, Rodriguez-Cabrera R, Tamayo J, Tugwell P (2008) Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. Osteoporos Int 19:269–276

    Article  CAS  PubMed  Google Scholar 

  17. Carlos F, Clark P, Maciel H, Tamayo JA (2009) Direct costs of osteoporosis and hip fracture: an analysis for the Mexican Social Insurance Health Care System. Salud Publica Mex 51(suppl 1):S108–S113

    PubMed  Google Scholar 

  18. Consejo Nacional de Población. Proyecciones de la población de México 2005–2050. http://www.conapo.gob.mx/00cifras/5.htm

  19. Instituto Nacional de Estadística y Geografía. Encuesta Nacional de Empleo y Seguridad Social (2009) Aguascalientes, Ags. México 2010

  20. Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. University of Sheffield, UK

    Google Scholar 

  21. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FRAX Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411

    Article  CAS  PubMed  Google Scholar 

  22. Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11:1–134

    CAS  PubMed  Google Scholar 

  23. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046

    Article  CAS  PubMed  Google Scholar 

  24. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. PharmacoEconomics 13:397–409

    Article  CAS  PubMed  Google Scholar 

  25. Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd (2010) Updated fracture incidence rates for the US version of FRAX. Osteoporos Int 21:25–33

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Instituto Mexicano del Seguro Social. Guía de Referencia Rápida (2009) Diagnóstico y Tratamiento de la Osteoporosis en el Adulto. Instituto Mexicano del Seguro Social, Guía de Referencia Rápida, Mexico City

  27. Sistema de Protección Social en Salud (2005) Elementos conceptuales, económicos y operativos. En: Unidad de Análisis Económico, Primerath edn. Secretaria de Salud, México, pp 11–38

    Google Scholar 

  28. Instituto Mexicano del Seguro Social. Costos Unitarios de Atención Médica. Diario Oficial de la Federación. Martes 18 de mayo de 2010

  29. Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Informe Financiero y Actuarial (2010) México, D.F., junio de 2010

  30. Instituto Nacional de Rehabilitación (2010) Tabulador de costos de recuperación. Secretaría de Salud, México

    Google Scholar 

  31. Instituto Mexicano del Seguro Social (2008) Costos Médico-Técnicos para los Grupos Relacionados con el Diagnóstico (GRD), http://www.imss.gob.mx/profesionales/Documents/GRD_IMSS.pdf

  32. Banco de México. Tipo de cambio FIX peso/dólar. http://www.banxico.org.mx/portal-mercado-cambiario/index.html

  33. Mueller D, Gandjour A (2009) Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. Value Health 12:1106–1117

    Article  PubMed  Google Scholar 

  34. Instituto Nacional de Estadística y Geografía. Indicadores de demografía y población. http://www.inegi.org.mx

  35. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475

    Article  PubMed  Google Scholar 

  36. Shi N, Foley K, Lenhart G, Badamgarav E (2009) Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45(6):1084–1090

    Article  PubMed  Google Scholar 

  37. Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413

    Article  PubMed  Google Scholar 

  38. Dilla T, Sacristán JA, Rentero ML (2007) Evaluación económica de teriparatida (forsteo®) en el tratamiento de la osteoporosis posmenopáusica. Rev Esp Econ Salud 6(1):57–64

    Google Scholar 

  39. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET (2010) Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics 28(5):395–409

    Article  PubMed  Google Scholar 

  40. Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, Brown JP, Goeree R (2012) The burden of illness of osteoporosis in Canada. Osteoporos Int. doi:10.1007/s00198-012-1931-z

Download references

Acknowledgments

We are grateful to Pfizer, S.A. de C.V. for their financial support of this study

Conflict of interest

This study was funded by an unrestricted grant from Pfizer, S.A. de C.V. Rosa María Galindo Suárez is employee of Pfizer, S.A. de C.V. Patricia Clark and Fernando Carlos act as advisors to and have received funding from several pharmaceutical companies involved in marketing products for treatment of osteoporosis, including Pfizer, S.A. de C.V.; Eli Lilly y Compañía de México, S.A. de C.V.; Productos Roche, S.A. de C.V.; and Novartis Farmaceutica, S.A. de C.V. Laura Gabriela Chico Barba has received honoraria from Pfizer, S.A. de C.V.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fernando Carlos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlos, F., Clark, P., Galindo-Suárez, R.M. et al. Health care costs of osteopenia, osteoporosis, and fragility fractures in Mexico. Arch Osteoporos 8, 125 (2013). https://doi.org/10.1007/s11657-013-0125-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11657-013-0125-4

Keywords

Navigation